Ashland Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Guillermo Novo
- Full Time Employees
- 2,900
- Sector
- Consumer non-durables
- Industry
- Food: specialty/candy
- Address
- 8145 Blazer Drive Wilmington DE United States 19808
- IPO Date
- Mar 17, 1980
- CIK
- 0001674862
- Website
- ashland.com
- Similar Companies
- Business
- Ashland Inc. operates as a global additives and specialty ingredients company serving consumer and industrial markets. The company manufactures and supplies a diverse portfolio of products, including specialty additives for architectural coatings, construction, energy, and automotive markets; life sciences products such as pharmaceuticals, nutrition, agricultural chemicals, and diagnostic films; personal care offerings encompassing biofunctionals, microbial protectants, skin care, sun care, oral care, and hair care solutions; and intermediates such as 1,4-butanediol (BDO) and related chemical derivatives. Ashland's Specialty Ingredients segment provides cellulose ethers, vinyl pyrrolidones, biofunctionals, and various polymers used in adhesives, coatings, pharmaceuticals, textiles, food and beverages, and nutraceuticals. Its consumer specialties division delivers products for oral care, hair care, skin care, and home care, while its industrial specialties serve packaging, automotive, and industrial applications. Founded in 2004 and headquartered in Wilmington, Delaware, Ashland operates across North America, Latin America, Europe, and Asia Pacific, with about 3,000 employees. The company focuses on higher-margin, resilient end markets through portfolio refinement and divestitures to streamline operations. Recently, Ashland completed the sale of its Avoca business in March 2025, aligning with its strategy to prioritize core specialty ingredients businesses. The company is pursuing restructuring and manufacturing optimization initiatives, including consolidating manufacturing operations and improving process productivity. Innovation is a key growth driver, with an ambitious plan to launch seven new products in 2025, targeting incremental sales growth through new and improved specialty ingredients, particularly in life sciences and personal care. Ashland reported double-digit growth in personal care sales driven by strong demand in skin and hair care sectors while managing challenges from customer destocking and structural market changes, especially in China. The company maintains a strong liquidity position with $300 million in cash and a total liquidity of $896 million as of late 2024. Its strategic focus includes expanding high-growth, sustainable, and biologics-related specialty ingredients, aiming to enhance profitability and generate significant sales improvements by 2027 through continuous innovation and operational efficiency enhancements. Ashland's long-term strategy emphasizes profitable growth via innovation, portfolio optimization, and manufacturing excellence to support its global footprint and diverse market presence.
Company News
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
What Ashland (ASH) Said on Its Q4 Earnings Call
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting